Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Report of the 2018-2019 Research and Graduate Affairs Committee.

O'Donnell JM, Anand S, Brown SD, Fuji KT, Guy RK, Kawaguchi-Suzuki M, Meier KE, Nelson CE, Vyas A, Block KF, Farrell DF.

Am J Pharm Educ. 2019 Dec;83(10):7595. doi: 10.5688/ajpe7595.

2.

Cultural Sensitivity and Global Pharmacy Engagement in the United States.

Alsharif NZ, Khanfar NM, Brennan LF, Chahine EB, Law M, Parekh J, Kawaguchi-Suzuki M, Hogue MD.

Am J Pharm Educ. 2019 May;83(4):7220. doi: 10.5688/ajpe7220.

3.

Cultural Sensitivity and Global Pharmacy Engagement in Asia: India, Indonesia, Malaysia, Philippines, and Vietnam.

Kawaguchi-Suzuki M, Hogue MD, Khanfar NM, Lahoz MR, Law MG, Parekh J, Zairina E, Hong J, Robles YR, Van Thang V.

Am J Pharm Educ. 2019 May;83(4):7215. doi: 10.5688/ajpe7215.

4.

Cultural Sensitivity and Global Pharmacy Engagement in Asia: China, Japan, South Korea, and Taiwan.

Kawaguchi-Suzuki M, Law MG, Prisco J, Head K, Fu L, Yumoto T, Kamei J, Yang M, Cheng KJ, Hogue MD.

Am J Pharm Educ. 2019 May;83(4):7214. doi: 10.5688/ajpe7214.

5.

Integration of mentored self-directed learning (MSDL) through both group and individual presentations in an accelerated modified block program.

Kawaguchi-Suzuki M, Fuentes DG, Gibbard RS, Backus D, Marcus K.

Curr Pharm Teach Learn. 2018 Jul;10(7):946-954. doi: 10.1016/j.cptl.2018.04.011. Epub 2018 Apr 26.

PMID:
30236433
6.

A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis.

Kawaguchi-Suzuki M, Cusi K, Bril F, Gong Y, Langaee T, Frye RF.

Front Pharmacol. 2018 Jul 17;9:752. doi: 10.3389/fphar.2018.00752. eCollection 2018.

7.

Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).

McDonough CW, Magvanjav O, Sá ACC, El Rouby NM, Dave C, Deitchman AN, Kawaguchi-Suzuki M, Mei W, Shen Y, Singh RSP, Solayman M, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Webb A, Scherer SE, Sadee W, Turner ST, Cooper-DeHoff RM, Gong Y, Johnson JA.

Circ Genom Precis Med. 2018 Apr;11(4):e001854. doi: 10.1161/CIRCGEN.117.001854.

8.

Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia.

Maxwell WD, Ramsey LB, Johnson SG, Moore KG, Shtutman M, Schoonover JH, Kawaguchi-Suzuki M.

Pharmacotherapy. 2017 Sep;37(9):1172-1190. doi: 10.1002/phar.1981. Epub 2017 Aug 23. Review.

PMID:
28672099
9.

Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.

Kawaguchi-Suzuki M, Bril F, Kalavalapalli S, Cusi K, Frye RF.

Aliment Pharmacol Ther. 2017 Jul;46(1):56-61. doi: 10.1111/apt.14111. Epub 2017 May 3.

10.

Effect of Low-Furanocoumarin Hybrid Grapefruit Juice Consumption on Midazolam Pharmacokinetics.

Kawaguchi-Suzuki M, Nasiri-Kenari N, Shuster J, Gmitter FG Jr, Cancalon P, de Oliveria F, Kight J, Handberg EM, Pepine CJ, Frye RF, Cooper-DeHoff RM.

J Clin Pharmacol. 2017 Mar;57(3):305-311. doi: 10.1002/jcph.807. Epub 2016 Sep 6.

11.

A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study.

Kawaguchi-Suzuki M, Bril F, Sanchez PP, Cusi K, Frye RF.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Oct 15;969:219-23. doi: 10.1016/j.jchromb.2014.08.019. Epub 2014 Aug 21.

PMID:
25195022
12.

The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity.

Kawaguchi-Suzuki M, Frye RF, Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, Markowitz JS.

Drug Metab Dispos. 2014 Oct;42(10):1611-6. doi: 10.1124/dmd.114.057232. Epub 2014 Jul 15.

13.

Current clinical evidence on pioglitazone pharmacogenomics.

Kawaguchi-Suzuki M, Frye RF.

Front Pharmacol. 2013 Nov 26;4:147. doi: 10.3389/fphar.2013.00147. eCollection 2013.

14.

Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.

McDonough CW, Gillis NK, Alsultan A, Chang SW, Kawaguchi-Suzuki M, Lang JE, Shahin MH, Buford TW, El Rouby NM, Sá AC, Langaee TY, Gums JG, Chapman AB, Cooper-DeHoff RM, Turner ST, Gong Y, Johnson JA.

PLoS One. 2013 Oct 7;8(10):e76984. doi: 10.1371/journal.pone.0076984. eCollection 2013.

15.

The role of pharmacogenetics in the treatment of chronic hepatitis C infection.

Kawaguchi-Suzuki M, Frye RF.

Pharmacotherapy. 2014 Feb;34(2):185-201. doi: 10.1002/phar.1349. Epub 2013 Sep 30. Review.

PMID:
24114761

Supplemental Content

Loading ...
Support Center